GoodRx Q2 revenue beats estimates; raises 2026 outlook

GoodRx Holdings

05/08/2026 22:09

Overview
US medication savings platform's Q2 revenue fell 1% yr/yr but beat analyst expectations
Adjusted EBITDA for Q2 beat analyst estimates; adjusted net income missed
Company raised full-year 2026 revenue and adjusted EBITDA guidance

Outlook
GoodRx raises full-year 2026 revenue guidance to $790 mln-$805 mln
Company lifts full-year 2026 adjusted EBITDA forecast to $240 mln-$250 mln
GoodRx expects lower unit economics to continue in the near term

Result Drivers
PHARMA DIRECT GROWTH - Co said Pharma Direct revenue rose 76% yr/yr, driven by expanded market penetration with pharma manufacturers and GLP-1 access programs
SUBSCRIPTION EXPANSION - Subscription revenue grew 39% yr/yr, led by condition-specific programs such as weight loss and more subscription plans
PRESCRIPTION TRANSACTIONS DECLINE - Prescription transactions revenue fell 26% yr/yr, due to fewer monthly active consumers, retail pharmacy changes, and a shift in investment toward subscriptions

Company press release: ID:nBw912yga

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$200.40 mln
$193.16 mln (13 Analysts)
Q2 Adjusted Net Income
Miss
$26.80 mln
$27.19 mln (10 Analysts)
Q2 Net Income
 
$8.50 mln
 
Q2 Adjusted EBITDA
Beat
$63.70 mln
$59.85 mln (13 Analysts)
Q2 Adjusted EBITDA Margin
 
31.80%
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 8 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the online services peer group is "buy."
Wall Street's median 12-month price target for GoodRx Holdings, Inc. is $3.00, about 10.2% below its August 4 closing price of $3.34
The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 7 three months ago

Reuters Recommended Reads
Aug 5 - Lilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo
Aug 5 - CVS Health Q2 revenue beats estimates, outlook raised
Aug 4 - P&G buys supplements maker Thorne for $3.8 billion as wellness push intensifies

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)